-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 3, June 2, Shanghai Sunshine Pharmaceutical Purchasing Network posted the "Announcement of the National Organization of Drug Joint Procurement Office on the issuance of the National Drug Centralized Procurement Document (GY-YD2021-2)", which means the fifth The batch of national drug collections was officially launched.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
According to the arrangement, the National Organization Drug Joint Procurement Office will officially start receiving application materials at 8 am on June 23 in Shanghai.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The selection rules are the same as before
Grasp the details and highlights
Judging from the calculation base of the agreed purchase amount in the first year, alfacalcidol oral normal-release dosage form, isosorbide mononitrate sustained-release and controlled-release dosage form, glipizide sustained-release and controlled-release dosage form, and glipizide oral regular-release dosage form , Budesonide inhalation, potassium chloride sustained-release and controlled-release dosage forms, etc.
are undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
are undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
However, there are differences in the rules for determining the first-year contracted purchase amount for each product and region, for azithromycin injection, fluconazole injection, linezolid glucose injection, moxifloxacin eye drops, tinidazole oral regular-release dosage form, etc.
11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
As for the selection rules that the industry is most concerned about, there are no too many differences compared with the fourth batch of national procurement.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
If the price of the shortlisted company meets one of the three conditions of "Comparable Unit Price" ≤ 1.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
Injection bidding attracts much attention
Pharmaceutical companies' strategies adapt to local conditions
Some analysts pointed out that because more than half of the injections involved in this centralized procurement, the market size affected may exceed 50 billion yuan.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
It can be expected that the fifth batch of six rounds of national procurement decline will continue to advance at an average rate of more than 50%.
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Experts suggest that since the cost of medicines covers a large number of items, pharmaceutical companies must first carefully study the composition behind the product cost, especially the manufacturing cost.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The fifth batch of nationally sourced drugs catalog
Medical Network News, June 3, June 2, Shanghai Sunshine Pharmaceutical Purchasing Network posted the "Announcement of the National Organization of Drug Joint Procurement Office on the issuance of the National Drug Centralized Procurement Document (GY-YD2021-2)", which means the fifth The batch of national drug collections was officially launched.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
According to the arrangement, the National Organization Drug Joint Procurement Office will officially start receiving application materials at 8 am on June 23 in Shanghai.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The selection rules are the same as before
Grasp the details and highlights
Judging from the calculation base of the agreed purchase amount in the first year, alfacalcidol oral normal-release dosage form, isosorbide mononitrate sustained-release and controlled-release dosage form, glipizide sustained-release and controlled-release dosage form, and glipizide oral regular-release dosage form , Budesonide inhalation, potassium chloride sustained-release and controlled-release dosage forms, etc.
are undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
are undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
However, there are differences in the rules for determining the first-year contracted purchase amount for each product and region, for azithromycin injection, fluconazole injection, linezolid glucose injection, moxifloxacin eye drops, tinidazole oral regular-release dosage form, etc.
11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
As for the selection rules that the industry is most concerned about, there are no too many differences compared with the fourth batch of national procurement.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
If the price of the shortlisted company meets one of the three conditions of "Comparable Unit Price" ≤ 1.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
Injection bidding attracts much attention
Pharmaceutical companies' strategies adapt to local conditions
Some analysts pointed out that because more than half of the injections involved in this centralized procurement, the market size affected may exceed 50 billion yuan.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
It can be expected that the fifth batch of six rounds of national procurement decline will continue to advance at an average rate of more than 50%.
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Experts suggest that since the cost of medicines covers a large number of items, pharmaceutical companies must first carefully study the composition behind the product cost, especially the manufacturing cost.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The fifth batch of nationally sourced drugs catalog
Medical Network News, June 3, June 2, Shanghai Sunshine Pharmaceutical Purchasing Network posted the "Announcement of the National Organization of Drug Joint Procurement Office on the issuance of the National Drug Centralized Procurement Document (GY-YD2021-2)", which means the fifth The batch of national drug collections was officially launched.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
Comparing the 60 varieties listed in the provinces' outflow report in April this year, 58 varieties were officially collected.
The two major varieties of mifepristone and carbetocin previously listed are temporarily absent.
However, the volume involved in the national procurement is still the largest and the largest number of products so far.
According to the arrangement, the National Organization Drug Joint Procurement Office will officially start receiving application materials at 8 am on June 23 in Shanghai.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The application information will be released at 10 o'clock on the same day and the supply area will be confirmed at 2 o'clock in the afternoon.
The selection rules are the same as before
The selection rules are the same as before Grasp the details and highlights
Grasp the details and highlights Judging from the calculation base of the agreed purchase amount in the first year, alfacalcidol oral normal-release dosage form, isosorbide mononitrate sustained-release and controlled-release dosage form, glipizide sustained-release and controlled-release dosage form, and glipizide oral regular-release dosage form , Budesonide inhalation, potassium chloride sustained-release and controlled-release dosage forms, etc.
are undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
Medicine Medicine Medicineare undoubtedly popular varieties, and the purchase base for some of the corresponding specifications has exceeded 200 million tablets (capsules/bags/sticks).
Among them, the purchase base of metoprolol oral regular-release dosage forms with a specification of 25 mg has reached 1.
2 billion tablets (tablets/bags/bottles).
Shaanxi Buchang High-tech, Yuanda Pharmaceuticals , and Zhuhai Homologous will cooperate with the original research manufacturer AstraZeneca.
This large variety of nearly 3 billion yuan launched a price fight.
However, there are differences in the rules for determining the first-year contracted purchase amount for each product and region, for azithromycin injection, fluconazole injection, linezolid glucose injection, moxifloxacin eye drops, tinidazole oral regular-release dosage form, etc.
11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
Enterprise business enterprise procurement procurement procurement11 According to the requirements: if the actual number of selected companies in the country is one, it is 40% of the calculation base of the first year's agreed purchase volume; if the number of actual selected companies in the country is 2, it is 50% of the calculation base of the first year's agreed purchase volume; If the number of selected enterprises is 3, it is 60% of the calculation base of the agreed purchase volume in the first year; if the actual number of selected enterprises in the country is 4 or more, it is 70% of the calculation base of the agreed purchase volume in the first year, which is less than other varieties.
10% of the purchase volume.
As for the selection rules that the industry is most concerned about, there are no too many differences compared with the fourth batch of national procurement.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
In this round of centralized procurement, the smallest specification of the same type in the catalog of purchased varieties is used as the representative specification, and the price converted to the smallest unit of measurement according to the drug price difference comparison rule is regarded as the "unit comparable price" (rounded to 4 decimal places).
According to the "comparable unit price", the order of the finalists and the confirmation of the supply area is determined according to the "comparable unit price".
The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
If the price of the shortlisted company meets one of the three conditions of "Comparable Unit Price" ≤ 1.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
8 times the lowest "Comparable Unit Price" of the same product, "Unit Declared Price" falling ≥ 50.
00%, and "Unit Comparable Price" ≤ RMB 0.
1000.
Obtain the qualifications to be selected.
Although the selection rules are consistent with the previous batches of centralized procurement, it is worth noting that, unlike the previous injections produced by the country, which only has a one-year procurement cycle, the procurement cycle involving injections in this round is the same as that of oral preparations, depending on the number of selected companies.
The procurement cycle is 1 to 3 years.
In the view of industry insiders, a larger market volume and longer procurement cycle will inevitably intensify the fierce competition of pharmaceutical companies.
Injection bidding attracts much attention
Injection bidding attracts much attention Pharmaceutical companies' strategies adapt to local conditions
Pharmaceutical companies' strategies adapt to local conditions Some analysts pointed out that because more than half of the injections involved in this centralized procurement, the market size affected may exceed 50 billion yuan.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
In the fourth batch of national centralized procurement, 8 injections including pantoprazole, hebromosol and parecoxib were included, and the average price reduction rate reached 75%.
With as many as 28 injections, the fierce price competition among pharmaceutical companies is self-evident.
After sorting out, the more competitive products include: 12 companies reviewed esomeprazole sodium for injection, 10 reviewed ceftazidime injections, 8 reviewed ceftriaxone sodium for injections, and 7 reviewed.
Azithromycin injection and docetaxel injection, etc.
It can be expected that the fifth batch of six rounds of national procurement decline will continue to advance at an average rate of more than 50%.
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Faced with the price war on the arrow, some industry insiders suggest that pharmaceutical manufacturers should base themselves on their own and make research and judgments in advance.
In response to national procurement, companies must first understand the goal they are pursuing, whether to win the national gold market at the lowest price, or to win the bid to occupy a place.
Obviously, the goals pursued by pharmaceutical companies are different, and the >
Experts suggest that since the cost of medicines covers a large number of items, pharmaceutical companies must first carefully study the composition behind the product cost, especially the manufacturing cost.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The second is to be familiar with the >Price is undoubtedly the first element of the confrontation.
Pharmaceutical companies must be familiar with the price trends of all provincial-level purchases and online listings in the past four years that each company has participated in, and be aware of the quotations of pharmaceutical companies.
Finally, the "blood drop" quotation of "killing one hundred enemies and self-defeating three thousand" is not desirable.
The quotation must be based on the actual status quo, but also based on rational thinking.
The winning rules have pushed pharmaceutical companies to the bottom line of irreducible decline.
In the past two batches of state-sourced companies, the practice of small price reductions in exchange for a large market is worth learning.
The fifth batch of nationally sourced drugs catalog
Fifth national mining drugs drugs drugs directory 
